Hikma Pharmaceuticals PLC

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E. Other stock markets 09:05:21 15/07/2024 pm IST			5-day change	1st Jan Change
1,837 ^GBX	0.00%		+1.55%	+2.68%

24/06	Teva launches generic version of Novo Nordisk's diabetes drug Victoza	RE
20/06	Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position'	MT

Gordon Brothers Group, LLC and New Mill Capital LLC acquired three buildings in Eatontown Industrial Park from Hikma Pharmaceuticals PLC.

January 02, 2019

Gordon Brothers Group, LLC and New Mill Capital LLC acquired three buildings in Eatontown Industrial Park from Hikma Pharmaceuticals PLC (LSE:HIK) on December 17, 2018. Gordon Brothers Group, LLC and New Mill Capital LLC completed the acquisition of three buildings in Eatontown Industrial Park from Hikma Pharmaceuticals PLC (LSE:HIK) on December 17, 2018.

Latest news about Hikma Pharmaceuticals PLC

Teva launches generic version of Novo Nordisk's diabetes drug Victoza	24/06	RE
Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position'	20/06	MT
Transcript : Hikma Pharmaceuticals PLC, Xellia Pharmaceuticals ApS, Xellia Pharmaceuticals - M&A Call	17/06
Hikma adds scale to US injectables business with Xellia acquisition	17/06	AN
Hikma to Buy Xellia Pharmaceuticals Assets for $135 Million	17/06	MT
Astra gets US drug approval; Ascential trades in line	17/06	AN
Hikma Pharmaceuticals PLC agreed to acquire Finished Dosage Form Business and Assets of Xellia Pharmaceuticals for approximately $190 million.	17/06	CI
Citigroup Hikes Hikma Pharmaceuticals PT, Maintains Buy Rating	11/06	MT
Morgan Stanley cuts Anglo American	11/06	AN
Egypt, UAE talks continuing over Ras El Hekma land deal	29/05	RE
HIKMA PHARMACEUTICALS : Time to capitalise on Hikma’s ongoing (share price) momentum	17/05
Deutsche Bank Starts Hikma Pharmaceuticals Coverage at Buy	03/05	MT
Jefferies cuts AJ Bell; Deutsche likes ConvaTec	03/05	AN
HIKMA PHARMACEUTICALS : Hikma’s Q1 progress appreciated by the markets	26/04
Hikma Pharmaceuticals plc Approves Final Dividend, Payable on 3 May 2024	25/04	CI
Hikma Pharmaceuticals backs outlook after making strong start to 2024	25/04	AN
Transcript : Hikma Pharmaceuticals PLC - Shareholder/Analyst Call	25/04
Hikma Pharmaceuticals Affirms FY24 Guidance	25/04	MT
Hikma Pharmaceuticals PLC Proposes Final Dividend for the Full Year 2023	25/04	CI
Hikma Pharmaceuticals plc Reiterates Earnings Guidance for the Year 2024	25/04	CI
Hikma Pharmaceuticals PLC Announces Executive Changes	15/04	CI
FTSE 100 Closes Up 0.12% Ahead of U.K. Jobs Data	11/03	DJ
The FTSE 100 Closed Up 0.4% as U.K. Announces Spring Budget Tax Cuts	06/03	DJ
Rakuten Medical, Inc. announced that it has received $45 million in funding from Dai-ichi Life Holdings, Inc., Mizuho Bank, Ltd., Hikma Pharmaceuticals PLC, Rakuten Ventures, SBI Holdings, Inc., Investment Arm and another investor	06/03	CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down	04/03	MT

Chart Hikma Pharmaceuticals PLC

Duration

Period

More charts

Company Profile

Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (45.3%); - brand name drugs (27.5%); - generic products taken orally (26.7%); - other (0.5%). Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

HIKMA PHARMACEUTICALS : Time to capitalise on Hikma’s ongoing (share price) momentum

May 17, 2024 at 06:40 pm IST

More Strategies

Ratings for Hikma Pharmaceuticals PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

23.85 USD

Average target price

28.96 USD

Spread / Average Target

+21.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HIKMA PHARMACEUTICALS PLC	+2.68%	529.25Cr
ELI LILLY AND COMPANY	+63.05%	86TCr
NOVO NORDISK A/S	+39.42%	63TCr
JOHNSON & JOHNSON	-4.78%	36TCr
MERCK & CO., INC.	+17.52%	32TCr
ABBVIE INC.	+8.43%	30TCr
ASTRAZENECA PLC	+14.19%	24TCr
ROCHE HOLDING AG	+5.81%	23TCr
NOVARTIS AG	+16.77%	23TCr
AMGEN INC.	+14.63%	18TCr

Other Pharmaceuticals

Hikma Pharmaceuticals PLC

Equities

HIK

GB00B0LCW083

Pharmaceuticals

Gordon Brothers Group, LLC and New Mill Capital LLC acquired three buildings in Eatontown Industrial Park from Hikma Pharmaceuticals PLC.

EPS Revisions

Quarterly revenue - Rate of surprise